UTHR (United Therapeutics) Long-Term Debt : $0 Mil (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Long-Term Debt?

United Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2024 was $0 Mil.

United Therapeutics's quarterly Long-Term Debt declined from Mar. 2024 ($200 Mil) to Jun. 2024 ($100 Mil) and declined from Jun. 2024 ($100 Mil) to Sep. 2024 ($0 Mil).

United Therapeutics's annual Long-Term Debt stayed the same from Dec. 2021 ($800 Mil) to Dec. 2022 ($800 Mil) but then declined from Dec. 2022 ($800 Mil) to Dec. 2023 ($300 Mil).

United Therapeutics Long-Term Debt Historical Data

The historical data trend for United Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Long-Term Debt Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

600.00

800.00

300.00

United Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															500.00	300.00	200.00	100.00	-

United Therapeutics (NAS:UTHR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

United Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

UTH:Germany UTH:Germany U2TH34:Brazil

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Executives

James Edgemond	officer: CFO and Treasurer	1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky	director
Martine A Rothblatt	director, officer: Chief Executive Officer
Christopher Causey	director
Michael Benkowitz	officer: President and COO	C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Raymond Dwek	director
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Nilda Mesa	director	C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Judy D. Olian	director	2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Louis W Sullivan	director
Paul A Mahon	officer: EVP & General Counsel
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Katherine J Klein	director	STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner	director	C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs	director, officer: President and COO